MiR-221-induced PUMA silencing mediates immune evasion of bladder cancer cells.
暂无分享,去创建一个
Xu Zhang | Xiaoyuan Xu | T. Zeng | Gongxian Wang | B. Fu | Wei-peng Liu | Xiaochen Zhou | Xu Zhang | Yibing Wang | Xia-li Zhang | Bin Lang | Ju Guo
[1] R. Askeland,et al. Anti‐interleukin‐10R1 monoclonal antibody in combination with bacillus Calmette–Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti‐tumour immunity , 2014, Clinical and experimental immunology.
[2] Han Liu,et al. PUMA and BIM Are Required for Oncogene Inactivation–Induced Apoptosis , 2013, Science Signaling.
[3] A. Filho,et al. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. , 2013, Cancer genomics & proteomics.
[4] S. Ryter,et al. Curcumin induces apoptotic cell death of activated human CD4+ T cells via increasing endoplasmic reticulum stress and mitochondrial dysfunction. , 2013, International immunopharmacology.
[5] M. Cannataro,et al. In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma , 2013, Oncotarget.
[6] Richard W. Kriwacki,et al. PUMA Binding Induces Partial Unfolding within BCL-xL to Disrupt p53 Binding and Promote Apoptosis , 2012, Nature chemical biology.
[7] M. Esmat,et al. The Value of Combined Use of Survivin mRNA and Matrix Metalloproteinase 2 and 9 for Bladder Cancer Detection in Voided Urine , 2012, Disease markers.
[8] A. Boulares,et al. Apoptotic DNA Fragmentation May Be a Cooperative Activity between Caspase-activated Deoxyribonuclease and the Poly(ADP-ribose) Polymerase-regulated DNAS1L3, an Endoplasmic Reticulum-localized Endonuclease That Translocates to the Nucleus during Apoptosis* , 2012, The Journal of Biological Chemistry.
[9] W. Xu,et al. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia , 2012, Cancer Gene Therapy.
[10] Zhihong Liu,et al. Glutathione S-transferase P1 gene polymorphism and bladder cancer susceptibility: an updated analysis , 2012, Molecular Biology Reports.
[11] Yuquan Wei,et al. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. , 2012, The Biochemical journal.
[12] J. Kaufman,et al. Immune escape strategies of a contagious cancer, devil facial tumour disease , 2012 .
[13] S. Inan,et al. Matrix metalloproteinase (MMP-2 and MMP-9) and steroid receptor expressions in feline mammary tumors , 2012, Biotechnic & histochemistry : official publication of the Biological Stain Commission.
[14] E. Ulukaya,et al. The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib , 2012, Tumor Biology.
[15] Cornelis F. M. Sier,et al. MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients , 2012, British Journal of Cancer.
[16] M. Swartz,et al. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. , 2012, Cell reports.
[17] M. Nuzzaci,et al. Apoptotic Effects of a Chimeric Plant Virus Carrying a Mimotope of the Hepatitis C virus Hypervariable Region 1: Role of Caspases and Endoplasmic Reticulum-Stress , 2012, Journal of Clinical Immunology.
[18] J. Chiang,et al. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. , 2012, Cancer research.
[19] C. Poyet,et al. 906 Bladder cancer micro environment influences maturation signature in lymphatic endothelial cells (LECs) by VEGF-C , 2012 .
[20] S. Takano. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation , 2012, Brain Tumor Pathology.
[21] B. Kandemir,et al. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. , 2011, Pathology, research and practice.
[22] H. Nakayama,et al. Apoptosis-dependent Externalization and Involvement in Apoptotic Cell Clearance of DmCaBP1, an Endoplasmic Reticulum Protein of Drosophila* , 2011, The Journal of Biological Chemistry.
[23] T. Jiang,et al. Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. , 2011, Oncology reports.
[24] Yung-Hyun Choi,et al. Methanol extract of Hydroclathrus clathratus suppresses matrix metalloproteinase-9 in T24 bladder carcinoma cells by suppressing the NF-κB and MAPK pathways. , 2011, Oncology reports.
[25] M. Campone,et al. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1 , 2011, Molecular Cancer.
[26] Barbara Majello,et al. Myc and PI3K/AKT signaling cooperatively repress FOXO3a-dependent PUMA and GADD45a gene expression , 2011, Nucleic acids research.
[27] K. Alitalo,et al. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. , 2011, Trends in molecular medicine.
[28] R. Seiler,et al. MMP-2 and MMP-9 in lymph-node-positive bladder cancer , 2011, Journal of Clinical Pathology.
[29] V. Baron,et al. Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo , 2011, The Prostate.
[30] Zhiwei Wang,et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. , 2011, Cancer research.
[31] P. Lin,et al. C/EBP-δ regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1α , 2011, Oncogene.
[32] S. Ylä-Herttuala,et al. 341 VEGF-C/VEGFR-3 Signaling Regulates Inflammatory Response in Development of Obliterative Airway Disease , 2011 .
[33] C. Kang,et al. PUMA is a novel target of miR-221/222 in human epithelial cancers. , 2010, International journal of oncology.
[34] J. Cheng,et al. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma , 2010, Molecular Cancer.
[35] Hui-ping Wang,et al. siRNA-mediated knockdown of VEGF-A, VEGF-C and VEGFR-3 suppresses the growth and metastasis of mouse bladder carcinoma in vivo. , 2010, Experimental and therapeutic medicine.
[36] Xiangyi Zheng,et al. Inhibition of TGF-β receptor I by siRNA suppresses the motility and invasiveness of T24 bladder cancer cells via modulation of integrins and matrix metalloproteinase , 2010, International Urology and Nephrology.
[37] M. Ismail,et al. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase‐2 in patients with bladder cancer , 2010, IUBMB life.
[38] T. Griffith,et al. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. , 2009, European journal of pharmacology.
[39] C. Kirkpatrick,et al. Endothelial VEGFR-3 expression in colorectal carcinomas is associated with hematogenous metastasis. , 2009, Oncology reports.
[40] J. Niederkorn. Immune escape mechanisms of intraocular tumors , 2009, Progress in Retinal and Eye Research.
[41] Bin Zhou,et al. [Relationships of human laryngeal squamous cell carcinomas with the expression of VEGF-C and VEGFR-3]. , 2009, Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi.
[42] M. Detmar,et al. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis. , 2009, The Journal of investigative dermatology.
[43] P. Pääkko,et al. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis. , 2008, Anticancer research.
[44] Zihua Hu,et al. MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components. , 2008, Molecular immunology.
[45] George A Calin,et al. Micro-RNA profiling in kidney and bladder cancers. , 2007, Urologic oncology.
[46] T. Turpeenniemi‐Hujanen,et al. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer. , 2007, Clinical biochemistry.
[47] Haidong Dong,et al. PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata , 2007, Cancer.
[48] G. Rabinovich,et al. Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.
[49] Y. Kudo,et al. VEGF-C is associated with lymphatic status and invasion in oral cancer , 2007, Journal of Clinical Pathology.
[50] A. Tangoku,et al. The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer , 2006, British Journal of Cancer.
[51] S. Harper,et al. VEGF-C promotes survival in podocytes. , 2006, American journal of physiology. Renal physiology.
[52] Hiroshi Sato,et al. Roles of membrane‐type matrix metalloproteinase‐1 in tumor invasion and metastasis , 2005, Cancer science.
[53] Jian Yu,et al. No PUMA, no death: implications for p53-dependent apoptosis. , 2003, Cancer cell.
[54] Federico Garrido,et al. MHC class I antigens, immune surveillance, and tumor immune escape , 2003, Journal of cellular physiology.
[55] D. Chopin,et al. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. , 2003, The American journal of pathology.
[56] N. Restifo,et al. Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.
[57] P. Krammer,et al. Immune escape of tumors: apoptosis resistance and tumor counterattack , 2002, Journal of leukocyte biology.
[58] K. Sugiyama,et al. Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. , 2001, European journal of cancer.
[59] K. Kinzler,et al. PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.
[60] K. Vousden,et al. PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.
[61] A. Okada. [Roles of matrix metalloproteinases and tissue inhibitor of metalloproteinase (TIMP) in cancer invasion and metastasis]. , 1999, Gan to kagaku ryoho. Cancer & chemotherapy.
[62] K. Alitalo,et al. Current biology of VEGF-B and VEGF-C. , 1999, Current opinion in biotechnology.
[63] K. Alitalo,et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. , 1999, The American journal of pathology.
[64] Tomoyuki Kato,et al. Matrix metalloproteinase 9 in mucosally invasive gastric cancer , 1998, Gastric Cancer.
[65] Brygida Berse,et al. Vascular permeability factor (VPF, VEGF) in tumor biology , 1993, Cancer and Metastasis Reviews.
[66] D. Tindall,et al. Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. , 2013, Cancer research.
[67] Xiangqi Li,et al. Expression of survivin and VEGF-C in breast cancer tissue and its relation to lymphatic metastasis. , 2012, European journal of gynaecological oncology.
[68] W. Shi,et al. Matrix metalloproteinase-9 silencing by RNA interference promotes the adhesive-invasive switch in HT1080 human fibrosarcoma cells. , 2012, Clinical laboratory.
[69] Yi-Xun Liu,et al. Apotosis in ovary. , 2011, Frontiers in bioscience.
[70] F. Alameda,et al. Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. , 2011, Human pathology.
[71] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[72] T. Tsubata. Apotosis of mature B cells. , 1999, International reviews of immunology.